European Commission clears proposed acquisition of Genzyme by Sanofi-Aventis
This article was originally published in Scrip
While the main players are still trying to work out whether a deal that is mutually acceptable to both sets of shareholders can be struck, the European Commission has declared it would not object to the proposed acquisition of Genzyme by Sanofi-Aventis on competition grounds. Consequently, the Commission has granted regulatory clearance under its Merger Regulation for the proposed acquisition.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.